Global Bile Duct Cancer Share Analysis 2025, Forecast To 2034
26 Mar, 2025
What Has Been the Growth of the Bile Duct Cancer Market So Far?
The bile duct cancer market has seen considerable growth due to a variety of factors.
• In recent times, the market size of bile duct cancer has witnessed a robust growth. This trend is expected to continue, elevating from $2.39 billion in 2024 to $2.60 billion in 2025, marking a compound annual growth rate (CAGR) of 9.1%.
The surge during the past years can be associated with factors such as heightened exposure to harmful chemicals, improved awareness around bile duct cancer, a growing elderly population, increasing instances of bile duct and pancreatic cancers, as well as amplified investments in the healthcare infrastructure.
What Is the Forecasted Market Size and Growth Rate for The Bile Duct Cancer Market?
The bile duct cancer market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the bile duct cancer market is projected to experience significant growth, expanding to a value of $3.63 billion by 2029 with a compound annual growth rate (CAGR) of 8.7%.
The growth during the forecasted period can be linked to a rise in bile duct cancer cases, an increase in incidences of liver cancer and biliary tract cancers (BTCs), elevated research and development activities, and a surge in the demand for advanced treatments. The market trends for the forecast period are expected to revolve around advancements in diagnostic and medical technologies, progress in endoscopic imaging techniques, technological innovations, and the further development of personalized medicine methods.
What Are The Primary Growth Drivers In The Bile Duct Cancer Market?
The escalating incidence of liver-related conditions is anticipated to boost the development of the bile duct cancer industry. Liver conditions encompass a variety of ailments that hinder the correct functioning of the liver, such as hepatitis, cirrhosis, fatty liver disease, and liver cancer. The escalating incidence of these conditions is predominantly attributed to factors like increased alcohol intake, poor diet, overweight, viral infections such as hepatitis, and inadequate regular exercise. Insights into bile duct cancer can aid in understanding these liver conditions by emphasizing the crucial function of bile ducts in liver operations, as any obstruction or dysfunction often results in liver complications like jaundice and cholestasis. For example, The House of Commons Library, a governmental institution based in the UK, reported in April 2024, that in 2022, 10,593 individuals aged below 75 years in England succumbed to liver disease, illustrating a continuing upsurge in mortality rates. The rate climbed from 21.2 per 100,000 population in 2021 to 21.4 per 100,000 in 2022. Hence, the escalating incidence of liver conditions is stimulating the progress of the bile duct cancer market.
What Are The Main Segments Of The Global Bile Duct Cancer Market?
The bile duct cancer market covered in this report is segmented –
1) By Type: Extrahepatic Bile Duct Cancer (eCCA), Intrahepatic Bile Duct Cancer (iCCA)
2) By Treatment Type: Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy
3) By Stage of Disease: Localized, Regional, Distant
4) By Diagnosis Type: Imaging Tests, Biopsy, Blood Tests
5) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Cancer Research Institutes
Subsegments:
1) By Extrahepatic Bile Duct Cancer (eCCA): Perihilar Cholangiocarcinoma (Klatskin Tumor), Distal Cholangiocarcinoma
2) By Intrahepatic Bile Duct Cancer (iCCA): Mass-Forming iCCA, Periductal Infiltrating iCCA, Intraductal Growth iCCA
What Emerging Trends Are Influencing The Growth Of The Bile Duct Cancer Market?
Prominent businesses in the bile duct cancer market are concentrating on developing novel solutions, such as targeted treatments, aimed at enhancing therapy effectiveness, minimizing side effects, and providing renewed hope for individuals suffering from this uncommon and difficult cancer. Targeted treatments are therapies constructed to focus on specific genes, proteins, or molecules that assist cancer cell growth. These treatments function by inhibiting the processes that allow cancer development, with a goal to halt tumor growth, decrease side effects, and better the treatment outcomes. For example, in August 2023, Taiho Pharmaceutical Co. Ltd., a pharmaceutical firm based in Japan, announced the introduction of LYTGOBI Tablets 4m, a FGFR Inhibitor. The tablet form of LYTGOBI presents an easy-to-administer oral option, boosting patient adherence and simplicity of therapy. This introduction offers a fresh treatment alternative for individuals suffering from advanced or metastatic bile duct cancer, particularly those having FGFR2 fusion or rearrangement mutations, thus dealing with a significant unfulfilled requirement in cancer treatment.
Who Are the Key Players In The Bile Duct Cancer Market?
Major companies operating in the bile duct cancer market are:
• AbbVie Inc.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Merck & Co. Inc.
• Boehringer Ingelheim International GmbH
• Eisai Co. Ltd.
• Genentech Inc.
• Jazz Pharmaceuticals plc. Incyte Corporation
• Exelixis Inc.
• Hutchison China MediTech Limited
• Zymeworks Inc.
• Mirati Therapeutics Inc.
• RenovoRx Inc.
• Spectrum Pharmaceuticals Inc.
• Specialised Therapeutics Pty Ltd
• Taiho Pharmaceutical Co. Ltd.
What Is The Most Dominant Region In The Bile Duct Cancer Market?
North America was the largest region in the bile duct cancer market in 2024. The regions covered in the bile duct cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.